Magnetic resonance spectroscopy in multiple sclerosis: window into the diseased brain

&NA; Magnetic resonance spectroscopy provides noninvasive insight into the regional and global biochemical alterations that are concomitants of the dynamic processes that underlie the evolution of fundamental pathologic changes in multiple sclerosis. These include now well‐recognized alterations of neuronal biochemical markers that accompany tissue destruction readily visualized by magnetic resonance imaging, but also dynamic changes in several metabolites that indicate pathological processes that precede the magnetic resonance imaging‐defined lesion, or completely escape current highresolution imaging Curr Opin Neurol 15:247‐251. © 2002 Lippincott Williams & Wilkins.

[1]  F. Barkhof,et al.  Cortical lesions in multiple sclerosis. , 1999, Brain : a journal of neurology.

[2]  P A Narayana,et al.  Proton MR spectroscopy of gadolinium‐enhanced multiple sclerosis plaques , 1992, Journal of magnetic resonance imaging : JMRI.

[3]  P M Matthews,et al.  Imaging axonal damage of normal-appearing white matter in multiple sclerosis. , 1998, Brain : a journal of neurology.

[4]  L. Krupp,et al.  Cognitive Dysfunction Lateralizes With NAA in Multiple Sclerosis , 2001, Applied neuropsychology.

[5]  F Barkhof,et al.  Neuronal damage in T1‐hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy , 1999, Annals of neurology.

[6]  G Helms,et al.  Volume correction for edema in single‐volume proton MR spectroscopy of contrast‐enhancing multiple sclerosis lesions , 2001, Magnetic resonance in medicine.

[7]  G. Comi,et al.  Glatiramer acetate reduces the proportion of new MS lesions evolving into “black holes” , 2001, Neurology.

[8]  P. Livrea,et al.  Axonal damage in multiple sclerosis plaques: a combined magnetic resonance imaging and 1H-magnetic resonance spectroscopy study , 2001, Journal of the Neurological Sciences.

[9]  Peter Kapeller,et al.  Preliminary evidence for neuronal damage in cortical grey matter and normal appearing white matter in short duration relapsing-remitting multiple sclerosis: a quantitative MR spectroscopic imaging study , 2001, Journal of Neurology.

[10]  B. Trapp,et al.  N‐acetylaspartate is an axon‐specific marker of mature white matter in vivo: A biochemical and immunohistochemical study on the rat optic nerve , 2002, Annals of neurology.

[11]  J S Wolinsky,et al.  Serial proton magnetic resonance spectroscopic imaging, contrast‐enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis , 1998, Annals of neurology.

[12]  E. Cabanis,et al.  Correlating multiple MRI parameters with clinical features: an attempt to define a new strategy in multiple sclerosis , 2001, Neuroradiology.

[13]  E. Cabanis,et al.  Localized proton magnetic resonance spectroscopy in relapsing remitting versus secondary progressive multiple sclerosis , 1999, Neurology.

[14]  B. Trapp,et al.  Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions , 2001, Annals of neurology.

[15]  U Klose,et al.  Proton MR spectroscopy with metabolite-nulling reveals elevated macromolecules in acute multiple sclerosis. , 2001, Brain : a journal of neurology.

[16]  E Moser,et al.  Multivoxel 3D proton spectroscopy in the brain at 1.5 versus 3.0 T: signal-to-noise ratio and resolution comparison. , 2001, AJNR. American journal of neuroradiology.

[17]  G. Barker,et al.  1H magnetic resonance spectroscopy of chronic cerebral white matter lesions and normal appearing white matter in multiple sclerosis , 1997, Journal of neurology, neurosurgery, and psychiatry.

[18]  M W Weiner,et al.  A serial study of new MS lesions and the white matter from which they arise , 1998, Neurology.

[19]  P M Matthews,et al.  Evidence for adaptive functional changes in the cerebral cortex with axonal injury from multiple sclerosis. , 2000, Brain : a journal of neurology.

[20]  B. Trapp,et al.  Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences , 2001, Current opinion in neurology.

[21]  G. Barker,et al.  Proton MR spectroscopy in clinically isolated syndromes suggestive of multiple sclerosis , 1999, Journal of the Neurological Sciences.

[22]  J. Frahm,et al.  Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy. , 1999, AJNR. American journal of neuroradiology.

[23]  G. Barker,et al.  Lesion heterogeneity in multiple sclerosis: a study of the relations between appearances on T1 weighted images, T1 relaxation times, and metabolite concentrations , 2000, Journal of neurology, neurosurgery, and psychiatry.

[24]  A. Compston,et al.  Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.

[25]  R I Grossman,et al.  Total brain N-acetylaspartate , 2000, Neurology.

[26]  J L Ostuni,et al.  Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis , 2001, Multiple sclerosis.

[27]  P M Matthews,et al.  Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. , 2001, Archives of neurology.

[28]  M W Weiner,et al.  1H MRSI comparison of white matter and lesions in primary progressive and relapsing-remitting MS , 2000, Multiple sclerosis.

[29]  J S Wolinsky,et al.  Grey matter abnormalities in multiple sclerosis: proton magnetic resonance spectroscopic imaging , 2001, Multiple sclerosis.